Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward C. Kuan is active.

Publication


Featured researches published by Edward C. Kuan.


International Forum of Allergy & Rhinology | 2018

Solitary chemosensory cells producing interleukin-25 and group-2 innate lymphoid cells are enriched in chronic rhinosinusitis with nasal polyps: Solitary chemosensory cells and ILC2s in CRSwNP

Neil N. Patel; Michael A. Kohanski; Ivy W. Maina; Vasiliki Triantafillou; Alan D. Workman; Charles Tong; Edward C. Kuan; John V. Bosso; Nithin D. Adappa; James N. Palmer; De’Broski R. Herbert; Noam A. Cohen

Chronic rhinosinusitis with nasal polyps (CRSwNP) is commonly characterized by type‐2 inflammation. It is established that group‐2 innate lymphoid cells (ILC2s) are a subset of immune cells important in orchestrating mucosal type‐2 response. IL‐25 is an epithelial‐derived cytokine that is a critical activator of ILC2s. Recent evidence demonstrates that specialized taster epithelial cells, such as solitary chemosensory cells (SCCs), may be producers of IL‐25. To elucidate the relationship between SCCs and ILC2s in CRSwNP, we sought to quantify ILC2s and SCCs to determine if these cell types are enriched in nasal polyps compared to healthy sinonasal mucosa.


International Forum of Allergy & Rhinology | 2017

Patient, disease, and treatment factors associated with overall survival in esthesioneuroblastoma

Ryan M. Carey; Joseph Godovchik; Alan D. Workman; Edward C. Kuan; Arjun K. Parasher; Jinbo Chen; James N. Palmer; Nithin D. Adappa; Jason G. Newman; Jason A. Brant

Esthesioneuroblastomas (ENB) are uncommon and data regarding outcomes are often limited to single‐institution series. The National Cancer Database (NCDB), which contains outcomes information from treatment centers across the United States, represents an opportunity to evaluate outcomes for rare diseases such as ENB across multiple institutions.


Laryngoscope | 2018

What is the appropriate timing for endoscopic and radiographic surveillance following treatment for sinonasal malignancies?: Surveillance for Sinonasal Malignancies

Arjun K. Parasher; Edward C. Kuan; Maie A. St. John; Bobby A. Tajudeen; Nithin D. Adappa

BACKGROUND Sinonasal malignancies are rare, representing only 3% of all head and neck neoplasms and approximately 1% of all malignancies. Given this low incidence and the diversity of pathologies, standardized protocols for post-treatment surveillance are lacking. Due to their advanced stage at presentation, sinonasal malignancies often have a poor prognosis, with recurrence rates ranging from 27% to 56%. Whereas the majority of recurrences occur within 2 to 3 years post-treatment, certain malignancies, such adenoid cystic carcinoma, olfactory neuroblastoma, and melanoma, have a propensity to recur much later. The majority of recurrences occur locally and represent the leading cause of diseasespecific mortality. Several factors, including complex anatomy, treatment-related changes, distortion due to resection and reconstruction, and sinonasal inflammation complicate surveillance for recurrence. Due to these unique aspects, accepted surveillance guidelines for head and neck malignancies may not be directly applicable for sinonasal malignancies. Accordingly, distinct guidelines for post-treatment endoscopic and radiographic surveillance are needed. LITERATURE REVIEW The current available evidence is limited at best. Whereas surveillance protocols have been better defined in the management of head and neck squamous cell carcinoma, the limited incidence and varied pathologies in sinonasal carcinomas have hindered the development of standardized protocols for post-treatment surveillance. Despite differences in tumor biology, treatment modalities and anatomical subsites, current clinical practice relies significantly on data published on general head and neck malignancies. Khalili and colleagues retrospectively evaluated the efficacy of endoscopic and imaging surveillance in patients with sinonasal malignancies. In this study, endoscopic follow-up was completed every 1 to 3 months for the first 2 years, 3 to 6 months for the next 3 years, and annually beyond year 5, whereas imaging was obtained every 3 to 6 months for the first 2 years, and at 6 months to yearly intervals afterward. In their review of 100 patients, 30 patients recurred, with 22 patients (73%) recurring locally; regional and distant metastasis represented 17% and 10% of recurrences, respectively. The majority of patients (63%) recurred within 2 years. Seventy-seven percent of recurrences were diagnosed with imaging, whereas only 17% and 3% were identified via endoscopy or physical examination, respectively. Although the specificity of endoscopy and imaging was similar at 89% and 90%, respectively, imaging had a significantly higher sensitivity (75% vs. 25%), accuracy (86% vs. 73%), and negative predictive value (92% vs. 78%) with P values <.05. However, identification of recurrence by endoscopy was critical, as it resulted in better prognosis, likely due to the superficial nature of these recurrences, thus making them amenable to reresection. The positive predictive value (PPV) was higher for imaging than nasal endoscopy, but the difference was not significant (72% vs. 43%, P 5 .07). Out of the imaging modalities, magnetic resonance imaging (MRI) had the highest PPV at 84%, significantly higher than computed tomography (CT) (44%) and positron emission tomography (PET)/CT (46%). However, PET/CT was critical in diagnosing distant recurrences in cases of mucosal melanoma. Furthermore, the presence of From the Department of Otolaryngology–Head and Neck Surgery (A.K.P.), University of South Florida, Tampa, Florida; Leonard Davis Institute of Health Economics (A.K.P.) and Department of Otorhinolaryngology–Head and Neck Surgery (E.C.K., N.D.A.), University of Pennsylvania, Philadelphia, Pennsylvania; Department of Head and Neck Surgery (M.A.S.), Jonsson Comprehensive Cancer Center (M.A.S.), and University of California Los Angeles Head and Neck Cancer Program (M.A.S.), University of California, Los Angeles Medical Center, Los Angeles, California; and the Department of Otorhinolaryngology–Head and Neck Surgery (B.A.T.), Rush University Medical Center, Chicago, Illinois, U.S.A.


Laryngoscope | 2018

When should a level IIB neck dissection be performed in treatment of head and neck squamous cell carcinoma?: Level IIb Neck Dissection

Brooke M. Su; Roxana Moayer; Edward C. Kuan; Maie A. St. John

BACKGROUND Cervical nodal metastases in head and neck squamous cell carcinoma (HNSCC) often follow a predictable pattern of spread. Appropriate management of neck disease is crucial for optimizing patient outcomes and survival. Selective neck dissection (SND) for the clinically negative neck (N0) has emerged as a technique to optimize locoregional control while minimizing morbidity such as injury to the spinal accessory nerve (SAN). Even when the SAN is spared, traction or pressure injury to the nerve can result in significant impairments in shoulder function for the patient. The anatomic boundaries of cervical level IIB include the skull base superiorly, the sternocleidomastoid muscle posterolaterally, and the SAN inferomedially. Dissection of nodal-bearing tissue from level IIB poses a risk of SAN injury and may not always be necessary based on the primary site and pattern of lymph node metastasis. Given the importance of oncologic control as well as quality-of-life considerations, when is it appropriate to include level IIB in elective or therapeutic neck dissections for HNSCC?


International Forum of Allergy & Rhinology | 2018

Risk of second primary malignancy in patients with sinonasal tumors: a population-based cohort study: Secondary malignancy after sinonasal cancer

Ashwin Ganti; Max A. Plitt; Edward C. Kuan; Hannah N. Kuhar; Pete S. Batra; Bobby A. Tajudeen

The 5‐year overall survival rate for patients with sinonasal cancers has remained around 50% for the last 3 decades. Prior studies on head and neck cancers have suggested that 1 reason for poor survival is the frequent development of second primary malignancies (SPMs). The purpose of this study is to assess overall and site‐specific risks of SPM following treatment of sinonasal malignancy.


Skull Base Surgery | 2018

Extraprimary Local Recurrence of Esthesioneuroblastoma: A Case Series

Ivy W. Maina; Brooke M. Su; Edward C. Kuan; Charles Tong; Michael A. Kohanski; John Y. K. Lee; Quang Luu; Jason G. Newman; James N. Palmer; Nithin D. Adappa


Skull Base Surgery | 2018

Risk Factors Associated with Intraoperative Cerebrospinal Fluid Leak in Endoscopic Pituitary Surgery

Karam W. Badran; Satvir Saggi; Edward C. Kuan; David W. Hsu; Marvin Bergsneider; Marilene Wang


Skull Base Surgery | 2018

Steroid-Eluting Stents in the Treatment of Recurrent Rathke’s Cleft Cyst

Elisabeth H. Ference; Karam W. Badran; Edward C. Kuan; Marvin Bergsneider; Marilene Wang


Skull Base Surgery | 2018

Unusual Presentation of Nasopharyngeal Angiofibroma in an Elderly Patient

Neil N. Patel; Alan D. Workman; Edward C. Kuan; Charles Tong; Michael A. Kohanski; Michael Feldman; David W. Kennedy; Nithin D. Adappa; James N. Palmer


Skull Base Surgery | 2018

Disorders Involving a Persistent Craniopharyngeal Canal: A Case Series

A. Kaufman; S. Poonia; Diego Cazzador; Michael A. Kohanski; Edward C. Kuan; Charles Tong; Daniele Borsetto; Enzo Emanuelli; James N. Palmer; Nithin D. Adappa

Collaboration


Dive into the Edward C. Kuan's collaboration.

Top Co-Authors

Avatar

Nithin D. Adappa

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

James N. Palmer

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Charles Tong

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Alan D. Workman

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Jason G. Newman

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Ryan M. Carey

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Arjun K. Parasher

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Bobby A. Tajudeen

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jason A. Brant

University of Pennsylvania

View shared research outputs
Researchain Logo
Decentralizing Knowledge